Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621000552886
Ethics application status
Approved
Date submitted
16/03/2021
Date registered
12/05/2021
Date last updated
12/05/2021
Date data sharing statement initially provided
12/05/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Ambulatory monitoring and management of chronic obstructive pulmonary disease
Query!
Scientific title
Feasibility assessment of an ambulatory monitoring and management of chronic obstructive pulmonary disease
Query!
Secondary ID [1]
303705
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
SPHERE COPD
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Obstructive Pulmonary Disease
321124
0
Query!
COPD
321125
0
Query!
Condition category
Condition code
Respiratory
318918
318918
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
A patient-operated smartphone application with a bluetooth-tethered fingertip pulse oximeter and peak flow meter. Patients will be trained on the operation of the devices and instructed to take once-daily measurements and answer a brief study-specific questionnaire for approximately 5 minutes per day for 14 weeks.
The data will be reviewed each day by a physician for early identification of acute worsening of patient condition. Upon identification of a potential episode of acute worsening of the patient condition a study physician will contact the patient via nominated phone number and discuss their condition and instruct them to follow/escalate to a new stage of their pre-designed COPD action plan (Lung Foundation Australia format) personalised to the patient for this study.
Adherence will be monitored via the physician and assessed via the frequency of data recorded.
Query!
Intervention code [1]
320007
0
Treatment: Devices
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
326856
0
Unstructured qualitative feedback via study-specific questionnaire. Participants will be prompted in free-text fields to discuss the perceived benefits and disadvantages of the platform and provide advice on improving acceptance, usability and engagement.
Query!
Assessment method [1]
326856
0
Query!
Timepoint [1]
326856
0
14 weeks
Query!
Primary outcome [2]
326857
0
Exit questionnaire score via study-specific questionnaire. Areas assessed include acceptance, usability, engagement and perceived benefits of use.
Query!
Assessment method [2]
326857
0
Query!
Timepoint [2]
326857
0
14 weeks
Query!
Secondary outcome [1]
392889
0
Change in FEV1 from median established in the first 2 weeks of system operation, as measured by the peak flow meter provided to the patient
Query!
Assessment method [1]
392889
0
Query!
Timepoint [1]
392889
0
Assessed daily for the first 2 weeks to establish median value, with the median value compared with the final values recorded at Week 14
Query!
Secondary outcome [2]
392890
0
Change in PEF from median established in the first 2 weeks of system operation, as measured by the peak flow meter provided to the patient
Query!
Assessment method [2]
392890
0
Query!
Timepoint [2]
392890
0
Assessed daily for the first 2 weeks to establish median value, with the median value compared with the final values recorded at Week 14
Query!
Secondary outcome [3]
392891
0
Change in SpO2 from median established in the first 2 weeks of system operation, as measured by the pulse oximeter provided to the patient
Query!
Assessment method [3]
392891
0
Query!
Timepoint [3]
392891
0
Assessed daily for the first 2 weeks to establish median value, with the median value compared with the final values recorded at Week 14
Query!
Secondary outcome [4]
392894
0
Number of true exacerbations as detected by the system and physician reviewing incoming data, and confirmed by site investigators/patient.
Query!
Assessment method [4]
392894
0
Query!
Timepoint [4]
392894
0
Week 14
Query!
Secondary outcome [5]
392895
0
Number of false exacerbations detected , as measured by the pulse oximeter provided to the patient, and confirmed by site investigators/patient.
Query!
Assessment method [5]
392895
0
Query!
Timepoint [5]
392895
0
Week 14
Query!
Secondary outcome [6]
392896
0
Number of undetected exacerbations reported by participants or their nominated GP and/or Specialist
Query!
Assessment method [6]
392896
0
Query!
Timepoint [6]
392896
0
Week 14
Query!
Secondary outcome [7]
392897
0
Change in the CAT score - a validated measure of patient-reported impact of COPD on their life.
Query!
Assessment method [7]
392897
0
Query!
Timepoint [7]
392897
0
The change in CAT score will be assessed between the values at baseline and Week 14 only
Query!
Secondary outcome [8]
392898
0
Adherence as measured by days without participant-initiated measurement, as automatically detected and reported by the smartphone application.
Query!
Assessment method [8]
392898
0
Query!
Timepoint [8]
392898
0
Week 14
Query!
Eligibility
Key inclusion criteria
1. Evidence of spirometrically confirmed airflow obstruction, defined as a post-bronchodilator FEV1/FVC ratio <0.7 and post-bronchodilator FEV1 between 30% and 70% predicted, recorded within 1 year of screening
2. Report one or more of the following symptoms within the preceding two weeks: shortness of breath, chronic cough and sputum
3. Hospitalisation for worsening COPD (exacerbation) on one or more occasions in the two years prior to commencement of study procedures
4. Be ambulatory and self-caring at the time of recruitment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Have experienced an exacerbation in the 30 days prior to screening
2. In the opinion of the investigator will not complete the study or adhere to the intervention
3. In the opinion of the investigator, have an inadequate mastery of English to communicate with study staff
4. Is unable to independently provide consent
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
13/05/2021
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
27/09/2021
Query!
Actual
Query!
Date of last data collection
Anticipated
3/01/2022
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
18933
0
Liverpool Hospital - Liverpool
Query!
Recruitment postcode(s) [1]
33437
0
2170 - Liverpool
Query!
Funding & Sponsors
Funding source category [1]
308119
0
Other Collaborative groups
Query!
Name [1]
308119
0
Sydney Partnership for Health, Education, Research and Enterprise (SPHERE)
Query!
Address [1]
308119
0
PO Box 3151
Liverpool, NSW 2170
Australia
Query!
Country [1]
308119
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
The George Institute for Global Health
Query!
Address
5/1 King St
Newtown, NSW 2042
AUSTRALIA
Query!
Country
Australia
Query!
Secondary sponsor category [1]
308875
0
None
Query!
Name [1]
308875
0
Query!
Address [1]
308875
0
Query!
Country [1]
308875
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
308105
0
SWSLHD HREC
Query!
Ethics committee address [1]
308105
0
Research Directorate
Locked Bag 7279
Eastern Campus
Liverpool BC NSW 1871
Query!
Ethics committee country [1]
308105
0
Australia
Query!
Date submitted for ethics approval [1]
308105
0
Query!
Approval date [1]
308105
0
29/11/2018
Query!
Ethics approval number [1]
308105
0
Query!
Summary
Brief summary
Prior to the COVID-19 pandemic there was growing recognition that at-home health monitoring programs based on a digital technologies could be used to empower community-based COPD patients to independently monitor their symptoms and act on rapid declines in health status.
The 'SPHERE COPD' study is an early pilot study aims to test the feasibility and user-friendliness of a newly developed portable and patient-operated disease monitoring system in a community setting, Centered around a novel smartphone application ("app"), patients can take daily measurements of their lung function, oxygen levels in their blood and track their symptoms and rescue medication use. the app will summarise the data for the participant and securely transmit it to a server for interpretation by a healthcare professional. Deteriorations in participant condition potentially indicative of an exacerbation may be identified by the healthcare professional and queried via a telephone call.
The downstream implications this study to completion are broad but have the potential to alter current approaches to COPD in the community. It may empower the individual to proactively identify an exacerbation and seek early medical assistance. It may also enhance their care by s providing physicians to access to longitudinal data on their patient’s condition between visits provides a powerful new tool with which they can more accurately tailor pharmacotherapies and written COPD action plans to optimise long-term outcomes.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
109554
0
Prof Christine Jenkins
Query!
Address
109554
0
The George Institute for Global Health
5/1 King St
Newtown, NSW 2042
AUSTRALIA
Query!
Country
109554
0
Australia
Query!
Phone
109554
0
+61 2 8052 4465
Query!
Fax
109554
0
Query!
Email
109554
0
[email protected]
Query!
Contact person for public queries
Name
109555
0
Mr Thomas Bradbury
Query!
Address
109555
0
The George Institute for Global Health
5/1 King St
Newtown, NSW 2042
AUSTRALIA
Query!
Country
109555
0
Australia
Query!
Phone
109555
0
+61 2 8052 4413
Query!
Fax
109555
0
Query!
Email
109555
0
[email protected]
Query!
Contact person for scientific queries
Name
109556
0
Mr Thomas Bradbury
Query!
Address
109556
0
The George Institute for Global Health
5/1 King St
Newtown, NSW 2042
AUSTRALIA
Query!
Country
109556
0
Australia
Query!
Phone
109556
0
+61 2 8052 4413
Query!
Fax
109556
0
Query!
Email
109556
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Sensitive and personal health information will be contained in individual participant data. At this time it is planned that only summaries of the de-identified data will be available.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF